1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Jiangsu Nhwa Pharmaceutical Co., LTD
  6. News
  7. Summary
    002262   CNE100000CG8

JIANGSU NHWA PHARMACEUTICAL CO., LTD

(002262)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Complix Signs Global Drug Discovery and Development Agreement with Jiangsu Nhwa Pharmaceutical Co. to Develop Novel Alphabody Therapeutics for Treatment of Cns Diseases

07/28/2021 | 04:41am EDT

Complix NV announced that it has signed a global collaboration and license agreement with Jiangsu Nhwa Pharmaceutical Co to develop Cell Penetrating Alphabodies (CPABs), able to cross the blood-brain barrier, for the improved treatment of diseases of the central nervous system (CNS). This agreement is an important corporate milestone for Complix, as it seeks to apply its industry leading CPAB platform in yet another major disease area, beyond oncology, autoimmunity, and viral diseases. Complix and Nhwa will collaborate to develop novel biotherapeutics against two selected CNS targets. Complix will apply its proprietary CPAB technology, that enables biologics to traverse membrane systems and act with high affinity and precision on disease targets that are considered intractable by current drug formats. The novel compounds to be developed under this collaboration, will be designed to cross the blood-brain barrier to address important disease targets in the central nervous system. Under the terms of the agreement, Complix has granted an exclusive license to Nhwa to develop, manufacture and commercialize the CPABs resulting from this collaboration in Greater China. Both companies retain joint development and commercialization rights for these CPABs in the rest of the world.


© S&P Capital IQ 2021
All news about JIANGSU NHWA PHARMACEUTICAL CO., LTD
05/06Jiangsu Nhwa Pharmaceutical Co., LTD Proposes Final Cash Dividend on A Shares for the Y..
CI
05/05Jiangsu Nhwa Pharmaceutical Co., Ltd Approves Cash Dividend for the Year 2021
CI
05/05Jiangsu Nhwa Pharmaceutical Co., LTD Approves the Election of Chen Guoxiang and Li Yula..
CI
04/22Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the First Quarter End..
CI
04/18Trevena Secures First $15 Million Tranche from Royalty-Based Financing with R-Bridge He..
MT
03/31Trevena Obtains Financing of Up to $40 Million From R-Bridge Healthcare Fund
MT
03/28Jiangsu Nhwa Pharmaceutical Co., Ltd Proposes Cash Dividend for 2021
CI
02/25Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the Full Year Ended D..
CI
01/27Trevena Seeks Chinese Approval for Acute Pain Management Injection
MT
2021Jiangsu Nhwa Pharma Signs Nearly $18 Million Deal to License Lundbeck's Schizophrenia D..
MT
More news
Financials
Sales 2022 4 378 M 652 M 652 M
Net income 2022 891 M 133 M 133 M
Net cash 2022 2 273 M 339 M 339 M
P/E ratio 2022 14,2x
Yield 2022 0,87%
Capitalization 12 706 M 1 893 M 1 893 M
EV / Sales 2022 2,38x
EV / Sales 2023 1,84x
Nbr of Employees 4 732
Free-Float 45,3%
Chart JIANGSU NHWA PHARMACEUTICAL CO., LTD
Duration : Period :
Jiangsu Nhwa Pharmaceutical Co., LTD Technical Analysis Chart | 002262 | CNE100000CG8 | MarketScreener
Technical analysis trends JIANGSU NHWA PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 12,61 CNY
Average target price 15,65 CNY
Spread / Average Target 24,1%
EPS Revisions
Managers and Directors
Jia Quan Sun General Manager & Director
Ai Hao Gao Chief Financial Officer
Peng Sheng Sun Chairman
Feng Shou Wang Chairman-Supervisory Board
Xu Sheng Kong Independent Director